[4] (Matrix Extracellular Phosphoglycoprotein) American Reagent Phase 2 150-patient started 4Q 2020 with NBCD (Nordic Bioscience) and is due to complete 3Q 2021.
[17] (Senolytic agents) Phase 2 study completed in 2015,[27] with the company claiming that the data suggested the ability to prevent cartilage loss.
Merck Nordic Bioscience (Proteinases Inhibitors) Phase 2 study started in 2019.
[46] A 2019 non-randomized study of 20 patients showed improvement in joint tissue health.
The Company is now in a position to accelerate recruitment by adding approximately 10 sites in the United Kingdom (UK) and Europe, with site initiation and subject screening expected to commence in 1H CY 2022.